Revolutionizing the Early Detection of Alzheimer’s Disease through Non-Invasive Biomarkers: The Role of Artificial Intelligence and Deep Learning
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is now classified as a silent pandemic due to concerning current statistics and future predictions. Despite this, no effective treatment or accurate diagnosis currently exists. The negative impacts of invasive techniques and the failure of clinical trials have prompted a shift in research towards non-invasive treatments. In light of this, there is a growing need for early detection of AD through non-invasive approaches. The abundance of data generated by non-invasive techniques such as blood component monitoring, imaging, wearable sensors, and bio-sensors not only offers a platform for more accurate and reliable bio-marker developments but also significantly reduces patient pain, psychological impact, risk of complications, and cost. Nevertheless, there are challenges concerning the computational analysis of the large quantities of data generated, which can provide crucial information for the early diagnosis of AD. Hence, the integration of artificial intelligence and deep learning is critical to addressing these challenges. This work attempts to examine some of the facts and the current situation of these approaches to AD diagnosis by leveraging the potential of these tools and utilizing the vast amount of non-invasive data in order to revolutionize the early detection of AD according to the principles of a new non-invasive medicine era.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
2023 Alzheimer's disease facts and figures
(2023) · Alzheimer's & Dementia · doi:10.1002/alz.13016 · Cited by 3,212
High performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Explainable artificial intelligence (XAI) in deep learning-based medical image analysis
van der Velden, B. H. M., Kuijf, H. J., Gilhuijs, K. G. A., & Viergever, M. A. (2022) · Medical Image Analysis · doi:10.1016/j.media.2022.102470 · Cited by 1,328
Alzheimer’s Disease: Epidemiology and Clinical Progression
Tahami Monfared, A. A., Byrnes, M. J., White, L. A., & Zhang, Q. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00338-8 · Cited by 629
A Deep Learning Model to Predict a Diagnosis of Alzheimer Disease by Using 18 F-FDG PET of the Brain
Ding, Y., Sohn, J. H., Kawczynski, M. G., Trivedi, H., Harnish, R., Jenkins, N. W., Lituiev, D., Copeland, T. P., Aboian, M. S., Mari Aparici, C., et al. (2019) · Radiology · doi:10.1148/radiol.2018180958 · Cited by 577
Digital biomarkers for Alzheimer’s disease: the mobile/wearable devices opportunity
Kourtis, L. C., Regele, O. B., Wright, J. M., & Jones, G. B. (2019) · npj Digital Medicine · doi:10.1038/s41746-019-0084-2 · Cited by 476 · cited 1×
“There is a growing body of literature suggesting that cognitive, behavioral, and motor changes may occur years prior to the onset of clinical symptoms in individuals with AD [17].”
BackgroundAlzheimer’s Disease: Key Insights from Two Decades of Clinical Trial Failures
Kim, C. K., Lee, Y. R., Ong, L., Gold, M., Kalali, A., & Sarkar, J. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215699 · Cited by 241 · cited 1×
“This complexity has posed significant challenges to the development of effective drug treatments for AD, as evidenced by the high rate of failure of drug candidates entering the AD drug-development pipeline over the past three decades [5].”
BackgroundAdvances in the development of new biomarkers for Alzheimer’s disease
Klyucherev, T. O., Olszewski, P., Shalimova, A. A., Chubarev, V. N., Tarasov, V. V., Attwood, M. M., Syvänen, S., & Schiöth, H. B. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00296-z · Cited by 241 · cited 1×
“Furthermore, analysis of blood-based samples can also provide early indications of AD pathology, by measuring levels of AD-related proteins such as A β and tau [14].”
BackgroundCurrent trends in blood biomarker detection and imaging for Alzheimer’s disease
Hu, S., Yang, C., & Luo, H. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114278 · Cited by 84
Liu, K. Y., Elliott, T., Knowles, M., & Howard, R. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101539 · Cited by 84
Cited by
Artificial Intelligence for Clinical Prediction: Exploring Key Domains and Essential Functions
Khalifa, M., & Albadawy, M. (2024) · Computer Methods and Programs in Biomedicine Update · doi:10.1016/j.cmpbup.2024.100148 · Cited by 201
“For instance, in the case of neurodegenerative diseases like Alzheimer ’ s, AI can detect subtle changes in brain imaging or cognitive function tests that might predict the rate at which the disease will progress [110].”
BackgroundOnciul, R., Tataru, C.-I., Dumitru, A. V., Crivoi, C., Serban, M., Covache-Busuioc, R.-A., Radoi, M. P., & Toader, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020550 · Cited by 113
“This drug is now undergoing preclinical trials, demonstrating AI’s ability to expedite the development pipeline and address critical therapeutic gaps in neurology [156].”
Revolutionizing Neurology: The Role of Artificial Intelligence in Advancing Diagnosis and Treatment
Kalani, M., & Anjankar, A. (2024) · Cureus · doi:10.7759/cureus.61706 · Cited by 48
Class balancing diversity multimodal ensemble for Alzheimer’s disease diagnosis and early detection
Francesconi, A., di Biase, L., Cappetta, D., Rebecchi, F., Soda, P., Sicilia, R., & Guarrasi, V. (2025) · Computerized Medical Imaging and Graphics · doi:10.1016/j.compmedimag.2025.102529 · Cited by 30
“In this context, advancements in artificial intelligence (AI) are increasingly pivotal in enhancing the early detection of MCI [9, 10].”
Chen, J., Han, X., Liu, Z., Zhou, C., Hu, R., Tabassam, S., Wyatt-Johnson, S. K., Oblak, A. L., Brutkiewicz, R. R., Lin, M., et al. (2026) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2025.3614233 · Cited by 2
Metadata
- Authors
- Vrahatis, A. G., Skolariki, K., Krokidis, M. G., Lazaros, K., Exarchos, T. P., & Vlamos, P.
- Venue
- Sensors
- Publisher
- MDPI AG
- Published
- 2023-04-22
- Volume
- 23
- Issue
- 9
- Pages
- 4184
- ISSN
- 1424-8220 (ISSN-L)
- OpenAlex
- W4366828958
- Cited by
- 166
- References
- 11
- FWCI
- 29.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.